Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVCN
CUSIPN/A
Phone604-270-4344
Debt
Debt-to-Equity Ratio-0.73
Current Ratio0.92
Quick Ratio0.90
Price-To-Earnings
Trailing P/E Ratio-0.11
Forward P/E Ratio-0.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.39 million
Price / Sales13.53
Cash FlowN/A
Price / CashN/A
Book Value($0.46) per share
Price / Book-0.09
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-22,900,000.00
Net Margins-1,687.90%
Return on Equity-85.81%
Return on Assets-52.15%
Miscellaneous
Employees147
Outstanding Shares1,860,190,000
Neovasc (NASDAQ:NVCN) Frequently Asked Questions
What is Neovasc's stock symbol?
Neovasc trades on the NASDAQ under the ticker symbol "NVCN."
How were Neovasc's earnings last quarter?
Neovasc Inc (NASDAQ:NVCN) issued its quarterly earnings results on Thursday, May, 10th. The medical equipment provider reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.10. The medical equipment provider had revenue of $0.34 million for the quarter, compared to the consensus estimate of $1.16 million. Neovasc had a negative return on equity of 85.81% and a negative net margin of 1,687.90%. View Neovasc's Earnings History.
When is Neovasc's next earnings date?
What price target have analysts set for NVCN?
2 Wall Street analysts have issued 12-month price targets for Neovasc's shares. Their forecasts range from $0.50 to $2.00. On average, they expect Neovasc's share price to reach $1.25 in the next year. View Analyst Ratings for Neovasc.
Are investors shorting Neovasc?
Neovasc saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 97,894,894 shares, an increase of 34.2% from the May 15th total of 72,937,221 shares. Based on an average daily trading volume, of 86,750,166 shares, the days-to-cover ratio is currently 1.1 days. View Neovasc's Current Options Chain.
Who are some of Neovasc's key competitors?
Some companies that are related to Neovasc include SeaSpine (SPNE), Iradimed (IRMD), Sensus Healthcare (SRTS), Apollo Endosurgery (APEN), Motus GI (MOTS), Invuity (IVTY), Restoration Robotics (HAIR), Alphatec (ATEC), Invo Bioscience (IVOB), Arch Therapeutics (ARTH), SANUWAVE Health, Inc. Common Stock (SNWV), CAS Medical Systems (CASM), Spectral Medical (EDTXF), Hancock Jaffe Laboratories (HJLI) and iCAD (ICAD).
Who are Neovasc's key executives?
Neovasc's management team includes the folowing people:
- Mr. Christopher Clark, CFO & Corp. Sec. (Age 46)
- Mr. Brian McPherson, Chief Operating Officer (Age 56)
- Ms. Vicki Bebeau, VP of Clinical and Regulatory Affairs
- Mr. Randy Lane, VP of R&D
- Mr. Alexei J. Marko, Advisor & Director (Age 49)
Has Neovasc been receiving favorable news coverage?
News stories about NVCN stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neovasc earned a media sentiment score of 0.05 on Accern's scale. They also gave news articles about the medical equipment provider an impact score of 46.20 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Neovasc's major shareholders?
Which major investors are buying Neovasc stock?
How do I buy shares of Neovasc?
Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neovasc's stock price today?
One share of NVCN stock can currently be purchased for approximately $0.0392.
How big of a company is Neovasc?
Neovasc has a market capitalization of $57.67 million and generates $5.39 million in revenue each year. The medical equipment provider earns $-22,900,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Neovasc employs 147 workers across the globe.
How can I contact Neovasc?
Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, Richmond A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-270-4344 or via email at [email protected]
MarketBeat Community Rating for Neovasc (NVCN)
MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote "Outperform" if you believe NVCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
